VBLT News and Press, Vascular Biogenics Ltd. From 03/23/22

Vascular Biogenics Ltd. (VBLT) Q4 2021 Earnings Conference Call March 22, 2022 8:30 a.m. ET Company Participants Dror Harats - CEO Sam Backenroth - CFO Dan Ferry - LifeSci Advisors, IR Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Susan Chor - Oppenheimer & Co. Swa...

The following slide deck was published by Vascular Biogenics Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Vascular Biogenics Ltd. 2021 Q4 - Results - Earnings Call Presentation

VBL Therapeutics press release (NASDAQ:VBLT): FY GAAP EPS of -$0.45 misses by $0.03. Revenue of $0.77M (-16.3% Y/Y) beats by $0.02M. At December 31, 2021,  cash, cash equivalents, short-term bank deposits and restricted bank deposits of $53.5 million. For further details see: VBL T...

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 Completed patient enrollment in the 409 patient OVAL Phase 3 registration ...

VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce FY earnings results on Wednesday, March 23rd, before market open. The consensus EPS Estimate is -$0.42 (+23.6% Y/Y) and the consensus Revenue Estimate is $0.75M (-18.5% Y/Y). For further details see: VBL Therapeutics FY 2021 Earnin...

AGFY, AYRO, CL, OTCQX:CRLBF, CTAS, EVGO, GIS, OTCPK:HNHAF, HTHT, HYZN, JKS, MOGO, PDSB, OTCPK:TCEHY, VBLT, WGO, YOU For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today a...

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today a...

VBL Therapeutics (NASDAQ:VBLT) said an independent data safety monitoring committee recommended to continue a phase 3 trial of its drug Ofra-vec to treat platinum-resistant ovarian cancer, following a review of data from 370 patients. The company noted that enrollment in the ph...

Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and Japan Top-line data from progression free survival (PFS) primary endpoint expected in 2H 2022 expected to have the potential to support a Biologics License Application (BLA) subm...